The burden of major depressive disorder is huge, as is clearly documented by World Health
Organization data. A major component of this burden is the episodic nature of depression …

Historically, the emphasis in treating depression has been focused on the acute phase of
treatment, with few published data on the continuation and maintenance phases of …

Canada and a lifetime prevalence of 8%. 1 The human cost of the illness in terms of
impaired social and emotional functioning cannot be emphasized enough, and the societal …

Although options for pharmacologic treatment for depression have grown seemingly
exponentially over the past several decades, the current armamentarium of antidepressants …

The good news is that advances in the treatment of depression in the past decade have led
to better recognition of those with depression, and also to a reduction in the number of …

Only 50% of depressed patients achieve remission of symptoms after 2 trials of
antidepressants. Therefore one half of patients are considered treatment resistant. Studies …

Antidepressants lead to improvement in about 70% of unselected patients with a depressive
syndrome. However, many of these patients would also improve with the passage of time …

Historically, the clinician's choice of antidepressant agent has been determined largely by
consideration of tolerability, given the perception that the therapeutic efficacy of the various …

Major depressive disorder (MDD) is an often chronic and/or recurrent disorder that is
associated with dysfunctions in multiple aspects of life including work and non-workrelated …

Depression is not only a common disorder, but also one that is readily treatable.
Antidepressant drugs play a major role in treatment, although concurrent use of …